ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Tampa, FL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Tampa, FL, USA:

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: revumenib
Drug: cobicistat

Phase 1, Phase 2

Syndax Pharmaceuticals
Syndax Pharmaceuticals

Tampa, Florida, United States and 47 other locations

(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib

Phase 3

AstraZeneca
AstraZeneca

Saint Petersburg, Florida, United States and 105 other locations

with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Tampa, Florida, United States and 108 other locations

The purpose of the study is to evaluate the safety and effectiveness of siltuximab for participants being treated for large granular lymphocytic leukemia...

Enrolling
Large Granular Lymphocyte Leukemia
Drug: Siltuximab

Early Phase 1

H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, United States

chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...

Active, not recruiting
Leukemia
Drug: Methotrexate
Drug: Thioguanine

Phase 2

Incyte
Incyte

Tampa, Florida, United States and 110 other locations

This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Azacitidine
Drug: Venetoclax

Phase 1, Phase 2

ImmunoGen
ImmunoGen

Tampa, Florida, United States and 30 other locations

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared wi...

Active, not recruiting
Leukemia, Myeloid, Acute
Leukemia, Myelomonocytic, Chronic
Drug: Pevonedistat
Drug: Azacitidine

Phase 3

Takeda
Takeda

Tampa, Florida, United States and 240 other locations

123 (CD123) in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clini...

Enrolling
Relapsed/Refractory Acute Myeloid Leukemia
Biological: UCART123v1.2

Phase 1

Cellectis

Tampa, Florida, United States and 8 other locations

This study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug (ruxolitinib) can improve outcomes of patient...

Active, not recruiting
Leukemia
Chronic Myelomonocytic Leukemia
Drug: Ruxolitinib

Phase 2

H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, United States and 4 other locations

The purpose of the study is to evaluate the safety and tolerability of the study drug, calaspargase pegol, when given with multi-agent chemotherapy.

Enrolling
Acute Lymphoblastic Leukemia
Drug: Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)
Drug: Rituximab

Phase 1

H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, United States

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems